Combining iNKT and CAR technology

admin_vjr_user — Wed, 24 Mar 2021 19:15:32 +0000

Marc van Dijk, PhD, Agenus, Cambridge, UK, describes ongoing research into enhancing the targeting and signalling capabilities of invariant natural killer T (iNKT) cells by modifying them with chimeric antigen receptor (CAR) technology in order to improve effectiveness in targeting solid tumors. The Virtual Systems for Immuno-Oncology (VISION) platform which involves using co-culture assays to recapitulate different elements of the tumor microenvironment is being used to drive the study and development of CAR-iNKT therapeutic candidates. Strategies to enhance the attraction of natural killer (NK) cells to the tumor site and improve the activity of iNKT cells expressing a CAR are also being investigated. This interview took place during the CAR-TCR Summit Europe 2021.

Investigating allogeneic iNKT cell therapy

admin_vjr_user — Wed, 24 Mar 2021 19:15:32 +0000

Marc van Dijk, PhD, Agenus, Cambridge, UK, describes INTELLIGENT invariant natural killer T (iNKT) cell technology, which are innate T-cells with natural killer (NK) cell properties, thus giving them the capacity to hone to diseased tissue sites and recruit components of the immune system to fight disease. This off-the-shelf, allogeneic cell therapy is currently being investigated in clinical trials for hematological malignancies such as multiple myeloma (NCT04754100), as well as acute respiratory syndrome in COVID-19 (NCT04582201). Preclinical research has also indicated the ability of iNKT cells to penetrate tissues and therefore their potential for targeting solid tumors, which could be combined with immune checkpoint antibodies in clinical studies in the future. This interview took place during the CAR-TCR Summit Europe 2021.

Marc van Dijk – VJRegenMed

Combining iNKT and CAR technology

Investigating allogeneic iNKT cell therapy